Information Provided By:
Fly News Breaks for February 18, 2020
Feb 18, 2020 | 06:56 EDT
Cantor Fitzgerald analyst Charles Duncan raised his price target for Intra-Cellular Therapies to $47 from $43 and reiterates an Overweight rating on the shares. After due diligence and speaking to a key opinion leader, Duncan is using a $44 daily pricing of Caplyta for the treatment of schizophrenia and he increased his projections for patients poorly controlled by current therapies and those seeking new treatment.
News For ITCI From the Last 2 Days
There are no results for your query ITCI